CTN-0001: Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
Walter Ling, MD
Lead Investigator
Integrated Substance Abuse Programs
University of California Los Angeles
lwalter@ix.netcom.com
For decades, clinicians have been frustrated by the inability to successfully detoxify opiate addicted patients because opiate-based detoxification, one of the most effective means to achieving that goal, has been unavailable outside the very restrictive confines of narcotic treatment programs. Bup/Nx shows promise as an effective aid for opiate detoxification; however, little data have been generated for the shorter-term use of Bup/Nx for this indication. Because the diversity of clinics in the CTN provides an unparalleled opportunity to conduct such a clinical endeavor, the utility of Bup/Nx in short term (13 day) detoxification versus clonidine in an inpatient setting was tested in the CTN.
Primary Findings
A total of 59 of the 77 (77%) in-patients assigned to the Bup/Nx condition achieved the treatment success criterion compared to 8 of the 36 (22%) assigned to clonidine. The study supports the benefits of Bup/Nx for opioid detoxification in inpatient treatment programs and illustrated important ways in which clinical research can be conducted in community treatment programs.
Primary Outcomes Article: Ling W, et al. A Multi-Center Randomized Trial of Buprenorphine-Naloxone versus Clonidine for Opioid Detoxification: Findings for the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005;100:1090-1110. [get article]
Related Resources
- CTN-0001 Study Protocol
- Publications in the Library about CTN-0001
- Study data from NIDA Data Share
- Blending Team Product: Short Term Opioid Withdrawal Using Buprenorphine
- Blending Team Product: Buprenorphine Suite
- ClinicalTrials.gov (NCT00032955)
- NIDA protocol page
Node Involvement
Lead Node(s):
All Participating Nodes: